上海医药
(601607)
| 流通市值：343.62亿 | | | 总市值：658.82亿 |
| 流通股本：19.32亿 | | | 总股本：37.03亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 30,517,706,443.04 | 29,263,734,941.59 | 31,337,367,133.62 | 27,040,490,007.31 |
| 衍生金融资产 | 2,596,393.11 | 6,371,535.14 | 3,436,387.25 | 5,221,726.92 |
| 应收票据及应收账款 | 74,842,530,072.65 | 77,427,177,737.01 | 78,823,719,484.03 | 76,282,441,826.8 |
| 其中：应收票据 | 1,908,648,955.48 | 1,268,588,471.74 | 1,409,207,805.83 | 1,392,602,573.15 |
| 应收账款 | 72,933,881,117.17 | 76,158,589,265.27 | 77,414,511,678.2 | 74,889,839,253.65 |
| 应收款项融资 | 2,320,106,012.96 | 1,941,354,874.99 | 1,562,015,687.9 | 1,553,187,140.94 |
| 预付款项 | 3,190,044,307.4 | 5,748,574,702.41 | 3,660,387,849.29 | 5,615,816,099.73 |
| 其他应收款合计 | 3,381,133,896.89 | 2,732,901,513.66 | 3,528,810,863.86 | 2,461,918,036.27 |
| 应收股利 | 239,065,993.48 | 391,138,217.3 | - | 54,058,025.13 |
| 存货 | 36,623,393,930.07 | 35,047,634,569.51 | 33,146,468,526.75 | 32,147,922,901.52 |
| 一年内到期的非流动资产 | 77,420,057.49 | 92,994,850.92 | 156,639,693.53 | 161,663,554.22 |
| 其他流动资产 | 1,326,776,412.93 | 964,465,989.39 | 1,124,275,094.46 | 832,586,860.88 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 162,433,862,348.46 | 164,628,820,577.63 | 164,781,723,168.36 | 157,170,379,297.84 |
| 非流动资产: | | | | |
| 长期应收款 | 227,939,569.6 | 199,089,327.03 | 200,858,612.45 | 204,349,642.8 |
| 长期股权投资 | 8,351,910,110.17 | 8,553,478,653.69 | 8,578,375,061.13 | 9,399,302,765.44 |
| 其他权益工具投资 | 55,416,725.2 | 53,797,240.28 | 56,382,940.45 | 52,873,747.88 |
| 其他非流动金融资产 | 2,195,371,867.75 | 2,124,808,342.06 | 2,168,130,907.7 | 2,163,929,013.84 |
| 投资性房地产 | 314,673,077.66 | 298,035,243.87 | 240,057,047.31 | 225,929,641.08 |
| 固定资产 | 12,155,054,666.68 | 11,123,260,339.84 | 11,307,368,958.74 | 11,389,327,284.48 |
| 在建工程 | 3,569,629,053.37 | 3,972,503,532.19 | 3,471,455,091.66 | 3,166,963,224.09 |
| 生产性生物资产 | 133,427,150.06 | 133,930,478.65 | 135,248,608.4 | 135,143,149.25 |
| 使用权资产 | 2,148,311,132.06 | 1,869,390,443.63 | 1,921,753,934.96 | 1,920,101,932.51 |
| 无形资产 | 6,050,835,947.46 | 5,989,554,088.04 | 6,120,506,873.42 | 6,110,167,521.49 |
| 开发支出 | 310,509,650.32 | 376,211,682.19 | 363,918,634.14 | 337,966,185.04 |
| 商誉 | 11,393,332,202.2 | 11,382,665,847.57 | 11,386,502,052.4 | 11,334,049,532.07 |
| 长期待摊费用 | 474,711,155.94 | 509,528,445.61 | 517,065,043.67 | 473,156,550.76 |
| 递延所得税资产 | 1,716,858,058.26 | 1,555,089,777.25 | 1,599,206,373.65 | 1,548,366,925.1 |
| 其他非流动资产 | 440,691,051.61 | 376,216,378.09 | 469,151,530.02 | 403,792,866.76 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 49,538,671,418.34 | 48,517,559,819.99 | 48,535,981,670.1 | 48,865,419,982.59 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 211,972,533,766.8 | 213,146,380,397.62 | 213,317,704,838.46 | 206,035,799,280.43 |
| 流动负债: | | | | |
| 短期借款 | 35,560,499,735.45 | 35,083,519,738.09 | 33,724,407,922.6 | 32,318,083,153 |
| 衍生金融负债 | 2,316,492.78 | 110,151.54 | 1,257,403.45 | 993,324.11 |
| 应付票据及应付账款 | 54,632,454,266.76 | 58,908,747,351.68 | 56,164,149,404.91 | 53,511,361,342.37 |
| 其中：应付票据 | 6,717,443,536.29 | 6,645,105,338.81 | 6,113,077,717.45 | 6,199,842,236.69 |
| 应付账款 | 47,915,010,730.47 | 52,263,642,012.87 | 50,051,071,687.46 | 47,311,519,105.68 |
| 合同负债 | 1,970,690,132.08 | 973,566,740.96 | 1,437,890,005.81 | 1,965,922,893.7 |
| 应付职工薪酬 | 1,783,979,964.7 | 1,400,167,377.38 | 1,413,278,642.49 | 1,153,659,606.43 |
| 应交税费 | 1,217,172,193.69 | 1,041,135,511.38 | 1,295,354,617.09 | 1,273,633,414.65 |
| 其他应付款合计 | 17,949,353,893.39 | 15,915,592,741.64 | 19,872,775,008.53 | 15,735,904,924.23 |
| 应付股利 | 247,130,022.22 | 319,736,981.8 | - | 278,016,660.21 |
| 一年内到期的非流动负债 | 2,963,475,811.09 | 2,937,610,462.72 | 4,234,825,090.02 | 2,129,027,173.24 |
| 其他流动负债 | 6,291,936,544.95 | 6,169,225,006.34 | 6,195,633,456 | 6,213,349,723.59 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 122,371,879,034.89 | 122,429,675,081.73 | 124,339,571,550.9 | 114,301,935,555.32 |
| 非流动负债: | | | | |
| 长期借款 | 5,786,154,730.58 | 7,487,613,491.5 | 6,869,962,559.2 | 8,596,134,663.56 |
| 租赁负债 | 1,550,076,681.63 | 1,312,971,609.45 | 1,322,310,985.71 | 1,401,988,160.65 |
| 长期应付款 | 8,163,467.74 | 8,121,514.2 | 8,128,733.7 | 8,440,638.86 |
| 长期应付职工薪酬 | 38,884,169.72 | 38,350,727.06 | 38,785,409.09 | 38,050,189.89 |
| 预计负债 | 39,585,088.27 | 26,798,144.36 | 26,255,410.24 | 24,005,518.4 |
| 递延收益 | 633,481,321.72 | 538,353,472.27 | 562,757,451.14 | 563,422,030.08 |
| 递延所得税负债 | 1,015,820,143.36 | 928,282,197.38 | 985,583,568.96 | 983,167,003.58 |
| 其他非流动负债 | 202,396,163.96 | 232,580,587.15 | 221,872,282.57 | 237,788,627.89 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 9,274,561,766.98 | 10,573,071,743.37 | 10,035,656,400.61 | 11,852,996,832.91 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 131,646,440,801.87 | 133,002,746,825.1 | 134,375,227,951.51 | 126,154,932,388.23 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,703,301,054 | 3,703,301,054 | 3,703,212,524 | 3,698,499,159 |
| 资本公积 | 29,187,649,155.53 | 29,168,809,495.26 | 29,164,167,422.22 | 29,114,509,187.93 |
| 其他综合收益 | -496,089,430.12 | -538,759,062.41 | -498,240,910.42 | -401,879,665.32 |
| 盈余公积 | 2,306,949,383.63 | 2,158,807,271.16 | 2,158,807,271.16 | 2,158,807,271.16 |
| 未分配利润 | 33,822,332,888.31 | 34,017,650,896.04 | 32,830,702,078.17 | 33,997,521,665.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 68,524,143,051.35 | 68,509,809,654.05 | 67,358,648,385.13 | 68,567,457,618.33 |
| 少数股东权益 | 11,801,949,913.58 | 11,633,823,918.47 | 11,583,828,501.82 | 11,313,409,273.87 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 80,326,092,964.93 | 80,143,633,572.52 | 78,942,476,886.95 | 79,880,866,892.2 |
| 负债和股东权益合计 | 211,972,533,766.8 | 213,146,380,397.62 | 213,317,704,838.46 | 206,035,799,280.43 |
| 公告日期 | 2024-03-29 | 2023-10-28 | 2023-08-30 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |